Detailed price information for Zimmer Biomet Holdings (ZBH-N) from The Globe and Mail including charting and trades.

The analyst offers a harsh assessment of Sarepta’s practices, calling into question its “opacity of clinical data, unique terminology for its clinical studies (which never matched with other ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Intercept Pharma (ICPT – Research Report) and ...

Detailed price information for Alpha Teknova Inc (TKNO-Q) from The Globe and Mail including charting and trades.

Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects.

The NASDAQ index, which is known as a proxy for technology stocks, is up 3% for the year as of January 25. That’s not particularly strong performance, and it makes the 10% decline in Apple Inc ...

Investigating Analyst Ratings: An Elaborate Study The standing of Sarepta Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions.

A high-level overview of Sarepta Therapeutics, Inc. (SRPT) stock. View (SRPT) real-time stock price, chart, news, analysis, analyst reviews and more.

Explore Sarepta Therapeutics analyst ratings and price targets (NASDAQ:SRPT) on Benzinga. Stay updated on expert opinions and forecasts for SRPT stock.

Pharma Catalent faces another possible revenue 'cliff' after Sarepta's gene therapy trial miss: analyst By Fraiser Kansteiner Nov 1, 2023 8:50am Catalent Sarepta Elevidys gene therapy ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report), AlloVir (ALVR – Research Report) and Bristol-Myers Squibb (BMY ...

Sarepta Therapeutics (SRPT) is under Wall Street’s microscope right now.Shares dropped by 49% in a single session last week, following the release of disappointing clinical trial results ...